AI Article Synopsis

  • Broadly Cross clade Neutralizing (BCN) antibodies could be key in developing vaccines and therapies against different strains of HIV.
  • In a study of 88 ART-naïve HIV-1 infected individuals, researchers found 12 samples with high neutralization effectiveness, including potent response against challenging tier-3 pseudoviruses.
  • Some identified antibodies targeted multiple regions of the virus, suggesting they can be harnessed for creating effective treatments and vaccine strategies, particularly from HIV-1 subtype C in India.

Article Abstract

Broadly Cross clade Neutralizing (BCN) antibodies are recognized as potential therapeutic tools and leads for the design of a vaccine that can protect human beings against various clades of Human Immunodeficiency Virus (HIV). In the present study, we screened plasma of 88 HIV-1 infected ART naïve individuals for their neutralization potential using a standard panel of 18 pseudoviruses belonging to different subtypes and different levels of neutralization. We identified 12 samples with good breadth of neutralization (neutralized >90% of the viruses). Four of these samples neutralized even the difficult-to-neutralize tier-3 pseudoviruses with great potency (GMT > 600). Analysis of neutralization specificities indicated that four samples had antibodies with multiple epitope binding specificities, viz. CD4-binding site (CD4BS), glycans in the V1/V2 and V3 regions and membrane proximal external region (MPER). Our findings indicate the strong possibility of identifying highly potent bNAbs with known or novel specificities from HIV-1 subtype C infected individuals from India that can be exploited as therapeutic tools or lead molecules for the identification of potential epitopes for design of a protective HIV-1 vaccine.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402285PMC
http://dx.doi.org/10.1038/srep46557DOI Listing

Publication Analysis

Top Keywords

cross clade
8
clade neutralizing
8
antibodies multiple
8
plasma hiv-1
8
hiv-1 subtype
8
subtype infected
8
infected individuals
8
therapeutic tools
8
broad potent
4
potent cross
4

Similar Publications

Receptor binding, structure, and tissue tropism of cattle-infecting H5N1 avian influenza virus hemagglutinin.

Cell

January 2025

Beijing Life Science Academy, Beijing 102200, China; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing 100101, China; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China. Electronic address:

The ongoing circulation of highly pathogenic avian influenza (HPAI) A (H5N1) viruses, particularly clade 2.3.4.

View Article and Find Full Text PDF

Beyond the role of bats as natural host reservoirs of infectious agents, the impact of viral spillover from other animal species to bats has been neglected. Given the limited virus-host specificity of astroviruses (AstVs) and their propensity for cross-species transmission, we hypothesized that AstVs could be transmitted within animal communities (rodents, birds, and bats) and that native endemic bats may be exposed to viruses hosted by other species. We investigated the presence of AstV RNA in 3,796 biological samples collected in Reunion Island from ( = 3421), an endemic free-tailed bat species, and also from small terrestrial mammals and birds: ( = 146), ( = 74), ( = 36), ( = 99), and ( = 20).

View Article and Find Full Text PDF

Zoonotic transmission of avian influenza viruses into mammals is relatively rare due to anatomical differences in the respiratory tract between species. Recently, clade 2.3.

View Article and Find Full Text PDF

Hybridisation is a source of genetic diversity, can drive adaptation to new niches and has been found to be a frequent event in lineages harbouring pathogenic fungi. However, little is known about the genomic implications of hybridisation nor its impact on pathogenicity-related traits. A common limitation for addressing these questions is the narrow representativity of sequenced genomes, mostly corresponding to strains isolated from infected patients.

View Article and Find Full Text PDF

Examining homology between MPXV and immunogenic VACV-derived peptides.

Vaccine

January 2025

Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:

The mpox virus (MPXV) came to global attention with the 2022 global outbreak. Current vaccination and post-exposure prophylaxis against MPXV consists of live vaccinia whole virus-based vaccines including ACAM2000®, JYNNEOS™, and LC16m8 originally developed against smallpox. Here, we analyzed 152 vaccinia-derived peptides we identified by mass spectrometry for homology with MPXV-1 and MPXV-2 sequences to evaluate their potential relevance to MPXV-specific immunity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!